MHLW Extends Roche's Tamiflu Valid-Use Period To Seven Years
This article was originally published in PharmAsia News
Executive Summary
The ministry of Health, Labor and Welfare Nov. 12 approved an extension of the valid-use period for Tamiflu from five years to seven years. The extension will be also applied to existing stockpiles. According to Chugai Pharmaceutical, the drug's importer and marketing company in Japan, there are no safety and effectiveness issues. Last year, U.S. FDA approved a two year extension of Tamiflu's expiration date. Since 2005, the Japanese government has spent ¥54.4 billion and stockpiled Tamiflu for 24 million people, and next year, the government plans to stockpile the drug for an additional 26 million. The extension will save several billion yen per year. (Click here for more - Japanese language
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.